Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Two studies examining the use of glucagon-like peptide-1 receptor agonists, including semaglutide, have found short- and long-term associations in orthopedic postoperative outcomes and general ...

SAN FRANCISCO — Patients who use GLP-1 receptor agonists (GLP-1 RAs) both before and after undergoing bariatric surgery experience greater weight loss than with surgery alone, new data suggested. The ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, ...

The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.

Preoperative GLP-1 therapy may reduce surgical risks in obese patients without increasing perioperative complications, offering a scalable weight management strategy. Updated ASA guidelines recommend ...

New research reveals how GLP-1 medications are reshaping the treatment landscape for conditions affecting the heart, kidney, liver, and more, hinting at a new era in chronic disease management.